Environmental Engineering Reference
In-Depth Information
39. Kullberg M, McCarthy R, Anchordoquy TJ (2014) Gene delivery to Her-2+ breast cancer
cells using a two-component delivery system to achieve specificity. Nanomedicine pii:
S1549-9634(14)00116-6. doi:
10.1016/j.nano.2014.02.013
40. Miyabe H, Hyodo M, Nakamura T, Sato Y, Hayakawa Y, Harashima H (2014) A new
adjuvant delivery system
for cancer immunotherapy.
J Control Release 184:20-27. doi:
10.1016/j.jconrel.2014.04.004
41. Lin CH, Al-Suwayeh SA, Hung CF, Chen CC, Fang JY (2013) Camptothecin-loaded
liposomes with
cyclic di-GMP/YSK05 liposome
'
'
-melanocyte-stimulating hormone enhance cytotoxicity toward and cellular
uptake by melanomas: an application of nanomedicine on natural product. J Tradit Comple-
ment Med 3(2):102-109. doi:
10.4103/2225-4110.110423
42. Tejera-Garcia R, Parkkila P, Zamotin V, Kinnunen PK (2014) Principles of rational design of
thermally targeted liposomes for local drug delivery. Nanomedicine pii: S1549-9634(14)
00131-2. doi:
10.1016/j.nano.2014.03.013
43. Mo R, Jiang T, Gu Z (2014) Enhanced anticancer efficacy by ATP-mediated liposomal drug
delivery. Angew Chem Int Ed Engl. doi:
10.1002/anie.201400268
44. Ahmed M, Cheung NK (2014) Engineering anti-GD2 monoclonal antibodies for cancer
immunotherapy. FEBS Lett 588(2):288-297. doi:
10.1016/j.febslet.2013.11.030
45. Brown BS, Patanam T, Mobli K, Celia C, Zage PE, Bean AJ, Tasciotti E (2014) Etoposide-
loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer
Biol Ther 15(7):851-861
46. Wolfram J, Suri K, Huang Y, Molinaro R, Borsoi C, Scott B, Boom K, Paolino D, Fresta M,
Wang J, Ferrari M, Celia C, Shen HJ (2014) Evaluation of anticancer activity of celastrol
liposomes in prostate cancer cells. J Microencapsul 31(5):501-507
47. Legut M, Lipka D, Filipczak N, Piwoni A, Kozubek A, Gubernator J (2014) Anacardic acid
enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines—
in vitro studies. Int J Nanomedicine 9:653-668. doi:
10.2147/IJN.S54911
48. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE (2014) Curcumin nanoformulations:
a review of pharmaceutical properties and preclinical studies and clinical data related to
cancer treatment. Biomaterials 35(10):3365-3383. doi:
10.1016/j.biomaterials.2013.12.090
49. Cai D, Gao W, He B, Dai W, Zhang H, Wang X, Wang J, Zhang X, Zhang Q (2014)
Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin deliv-
ery in breast cancer therapy. Biomaterials 35(7):2283-2294. doi:
10.1016/j.biomaterials.
50. Bartneck M, Peters FM, Warzecha KT, Bienert M, van Bloois L, Trautwein C, Lammers T,
Tacke F (2014) Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflam-
matory cytokine response, and migratory properties of primary human macrophages.
Nanomedicine 10(6):1209-1220. doi:
10.1016/j.nano.2014.02.011
51. Schiener M, Hossann M, Viola JR, Ortega-Gomez A, Weber C, Lauber K, Lindner LH,
Soehnlein O (2014) Nanomedicine-based strategies for treatment of atherosclerosis. Trends
Mol Med 20(5):271-281
52. Garg T (2014) Current nanotechnological approaches for an effective delivery of bio-active
drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol 20:1-8
53. Ozbakir B, Crielaard BJ, Metselaar JM, Storm G, Lammers T (2014) Liposomal corticoste-
roids for the treatment of inflammatory disorders and cancer. J Control Release 190:624-36.
54. Sun Y, Fox T, Adhikary G, Kester M, Pearlman E (2008) Inhibition of corneal inflammation
by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol 83(6):1512-1521. doi:
10.
55. Nakagishi Y, Shimizu M, Kasai K, Miyoshi M, Yachie A (2014) Successful therapy of
macrophage activation syndrome with dexamethasone palmitate. Mod Rheumatol Apr 23.
[Epub ahead of print]
56. Date AA, Destache CJ (2013) A review of nanotechnological approaches for the prophylaxis
of HIV/AIDS. Biomaterials 34:6202-6228. doi:
10.1016/j.biomaterials.2013.05.012
ʱ
